The stock of Psyence Biomedical Ltd. (PBM) has seen a 35.06% increase in the past week, with a 11.54% gain in the past month, and a -20.00% decrease in the past quarter. The volatility ratio for the week is 30.36%, and the volatility levels for the past 30 days are at 16.17% for PBM. The simple moving average for the past 20 days is 33.83% for PBM’s stock, with a -83.97% simple moving average for the past 200 days.
Is It Worth Investing in Psyence Biomedical Ltd. (NASDAQ: PBM) Right Now?
The 36-month beta value for PBM is at -0.10.
The public float for PBM is 4.70M, and currently, shorts hold a 5.15% of that float. The average trading volume for PBM on May 06, 2024 was 3.74M shares.
PBM) stock’s latest price update
Psyence Biomedical Ltd. (NASDAQ: PBM) has experienced a decline in its stock price by -8.66 compared to its previous closing price of 1.27. However, the company has seen a gain of 35.06% in its stock price over the last five trading days. InvestorPlace reported 2024-03-08 that Lesser-known life science and biotechnology firm Psyence Biomedical (NASDAQ: PBM ) skyrocketed on Friday following a potentially pivotal development. Australian regulators gave the green light for the company to conduct a Phase 2B study for its psychedelics-based treatment.
PBM Trading at 18.39% from the 50-Day Moving Average
After a stumble in the market that brought PBM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.03% of loss for the given period.
Volatility was left at 16.17%, however, over the last 30 days, the volatility rate increased by 30.36%, as shares surge +17.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +113.51% upper at present.
During the last 5 trading sessions, PBM rose by +35.06%, in comparison to the 20-day moving average, which settled at $0.8755. In addition, Psyence Biomedical Ltd. saw -87.45% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PBM
Equity return is now at value 1.27, with 1.13 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.01.
Conclusion
In conclusion, Psyence Biomedical Ltd. (PBM) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
